坏死性凋亡在肿瘤放化疗中的研究进展与思考

Progress in research on necroptosis as a target for cancer radiotherapy and chemotherapy

肿瘤具有对程序性细胞死亡的抵抗作用,这是肿瘤细胞会产生放化疗耐受的原因之一.细胞程序性死亡不仅包括依赖含半胱氨酸的天冬氨酸蛋白水解酶（caspase）的细胞凋亡,也包括一种最近研究热门的非依赖caspase的死亡形式——坏死性凋亡.目前研究发现坏死性凋亡是由受体相互作用蛋白1 （RIP1）、受体相互作用蛋白3（RIP3）以及混合谱系激酶结构域蛋白（MLKL）进行调控.笔者简要地总结了目前国内外坏死性凋亡相关的研究进展,为坏死性凋亡作为一种肿瘤放化疗新靶点的深入研究提供新思路.

A characteristic of cancer is resistance to programmed cell death,which sustains cell survival through oncogenic transformation and therapeutic resistance.Recent studies have shown that programmed cell death is not limited to caspase-dependent apoptosis.Necroptosis,a caspase-independent form of cell death,is regulated by receptor interacting protein 1,receptor interacting protein 3,and mixed lineage kinase domain-like proteins.This review summarized current research studies on necroptosis to provide perspectives for the development of novel tumor radiotherapy and chemotherapy strategies that target this process.